# Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Study · id `cardio:ct-nct02585778` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02585778](<https://clinicaltrials.gov/study/NCT02585778>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02585778

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 517 participants.

## Technical summary

Registry record NCT02585778. Randomized; double masking; primary purpose treatment. Start 2015-10-23 (actual); primary completion 2017-04-03 (actual). Results posted on 2018-05-17.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 517 participants (enrolled count; ClinicalTrials.gov record NCT02585778, source copy `cardio:ctgov-nct02585778-2018-05-17`, retrieved 2026-10-31)
- Started: 2015-10-23 (actual) (ClinicalTrials.gov record NCT02585778, source copy `cardio:ctgov-nct02585778-2018-05-17`, retrieved 2026-10-31)
- Primary completion: 2017-04-03 (actual) (ClinicalTrials.gov record NCT02585778, source copy `cardio:ctgov-nct02585778-2018-05-17`, retrieved 2026-10-31)
- Completion: 2017-04-03 (actual) (ClinicalTrials.gov record NCT02585778, source copy `cardio:ctgov-nct02585778-2018-05-17`, retrieved 2026-10-31)
- Results first posted: 2018-05-17 (ClinicalTrials.gov record NCT02585778, source copy `cardio:ctgov-nct02585778-2018-05-17`, retrieved 2026-10-31)
- Countries: United States; Austria; Belgium; France; Germany; Italy; Netherlands; Spain; Switzerland; United Kingdom (ClinicalTrials.gov record NCT02585778, source copy `cardio:ctgov-nct02585778-2018-05-17`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02585778-2018-05-17`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
- Condition: Hypercholesterolaemia
- Intervention (Drug): Alirocumab
- Intervention (Drug): Placebo
- Intervention (Drug): Lipid-Modifying Therapy (LMT)
- Intervention (Drug): Antihyperglycemic Drug
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY
- Collaborator: Regeneron Pharmaceuticals
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Alirocumab (`cardio:alirocumab`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)
- Registry lists this organization as a collaborator: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial (`cardio:pubmed-28905478`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 50dab2e9f8a96a44d8cfd90acf0d8646de773ee91544e432b7845236cd2fd627
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
